Kura Oncology menin-MLL1 inhibitor
oral, QD menin-MLL1 inhibitor Ph. I/II for leukemia from HTS and SBDD ziftomenib (KO-539) Kura Oncology, San Diego, CA / UMich (Grembecka Lab)
Molecules of the Month - 2022 Molecules of the Year Nominees
- BMS TYK2 inhibitor
- Mirati/Array/Pfizer KRAS(G12D) inhibitor
- Madrigal THRβ-selective agonist
- GBT/Pfizer HbS polymerization inhibitor
- Myokardia/BMS cardiac myosin inhibitor
- Kura Oncology menin-MLL1 inhibitor
- LEO Pharma IL-17A modulator
- YourChoice/UMN RAR-α antagonist
- Cerevel/Pfizer M4 positive allosteric modulator
- ChemoCentryx C5aR antagonist
- BMS TYK2 inhibitor
- Mirati/Array/Pfizer KRAS(G12D) inhibitor
- Madrigal THRβ-selective agonist
- GBT/Pfizer HbS polymerization inhibitor
- Myokardia/BMS cardiac myosin inhibitor
- Kura Oncology menin-MLL1 inhibitor
- LEO Pharma IL-17A modulator
- YourChoice/UMN RAR-α antagonist
- Cerevel/Pfizer M4 positive allosteric modulator
- ChemoCentryx C5aR antagonist